HMP Market Access Insights

In the 2025 Payer Oncology Trend Report, we analyze how health plans and PBMs are navigating the shifting landscape of branded cancer drug management. To deepen our findings, we spoke with industry experts Michael Kolodziej, MD, and Ira Klein, Vice President, Medical Affairs & Payer Relations at Tempus, who shared their perspectives on the data, key trends, and what these insights mean for manufacturers moving forward.

In this episode, MAI team members share thought-provoking quotes and insights gathered from conversations this year with key decision makers involved with IDNs, Community Oncology Practices, Payers & Pathways.

In part 3 of this 3-part podcast series, HMP Executive Vice President Lee Blansett and special guest John Hennessy—health system, provider and oncology strategist—conclude their conversation on oncology practice economics, discussing emerging models for success (e.g., utilization of advanced therapies) and manufacturer implications.

In part 2 of this 3-part podcast series, HMP Executive Vice President Lee Blansett and special guest John Hennessy—health system, provider and oncology strategist—continue their exploration of oncology practice economics, focusing on practices’ operational realities.

In part 1 of this 3-part podcast series, HMP Executive Vice President Lee Blansett and special guest John Hennessy—health system, provider. and oncology strategist—explore the current state of oncology practice economics.

 In part 2 of this 2-part podcast series, HMP MAI Director of Payer Insights Chris Van Denburg and special guest Tina Valbh – pharmacist and oncology patient – continue their exploration of oncology patient support services programs, with several key pieces of advice for biopharmaceutical companies.

In part 1 of this 2-part podcast series, HMP MAI Director of Payer Insights Chris Van Denburg and special guest Tina Valbh – pharmacist and oncology patient – explore her experiences with and advice for oncology patient support services programs, emphasizing those provided by biopharmaceutical companies.

HMP MAI Director of Payer Insights Chris Van Denburg and special guest and notable specialist Carole Tremonti, RN, MBA, investigate key insights about what clinical decision support systems—and AI—are and are NOT, what we can rely on them for currently, and how biopharmaceutical companies with oncology products can prepare for success related to these advances. 

In this episode, you will hear from the research leads for each of our key customer segments about 3 notable quotes they heard from conversations this year with providers, payers, and administrators in the oncology sector.

In this episode, we provide highlights on key insights from our 2023 Community Oncology Annual Trend Report, including why it's important for pharma companies to tailor their approach with community oncology groups based on what archetype they fall under.